New hepatitis b drug enters first human safety tests
Disease control
Recruiting now
This early-stage study tests a new drug called GIGA-2339 in people with chronic hepatitis B. The main goal is to see if it is safe and how the body processes it. About 48 adults will receive either the drug or a placebo, given through a vein. Participants must have had hepatitis …
Phase: PHASE1 • Sponsor: GigaGen, Inc. • Aim: Disease control
Last updated May 04, 2026 16:18 UTC